Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease

Summary We undertook a comprehensive clinical and biological investigation of serial medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, and all patients in this group died of rapidly progressive disease postrelapse. To study this interaction, we investigated a transgenic model of MYCN-driven medulloblastoma and found spontaneous development of Trp53 inactivating mutations. Abrogation of p53 function in this model produced aggressive tumors that mimicked characteristics of relapsed human tumors with combined P53-MYC dysfunction. Restoration of p53 activity and genetic and therapeutic suppression of MYCN all reduced tumor growth and prolonged survival. Our findings identify P53-MYC interactions at medulloblastoma relapse as biomarkers of clinically aggressive disease that may be targeted therapeutically.

[1]  F. Berthold,et al.  Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. , 2009, Neuro-oncology.

[2]  D. Rowitch,et al.  Neuroblastoma Mycn Protein and Blocks Malignant Progression in Inhibition of Phosphatidylinositol 3-Kinase Destabilizes , 2006 .

[3]  G. Evan,et al.  Temporal dissection of p53 function in vitro and in vivo , 2005, Nature Genetics.

[4]  D. Ellison,et al.  Combined genome‐wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma , 2006, Genes, chromosomes & cancer.

[5]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[6]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[7]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[8]  Matthew J. Betts,et al.  Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.

[9]  David T. W. Jones,et al.  Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Lichter,et al.  TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Wang,et al.  Loss of Heterozygosity Analysis of Chromosome 17p13.1–13.3 and its Correlation with Clinical Outcome in Medulloblastomas , 2004, Journal of Neuro-Oncology.

[12]  M. Cole,et al.  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma , 2010, Clinical Cancer Research.

[13]  Erin F. Simonds,et al.  Drugging MYCN through an allosteric transition in Aurora kinase A. , 2014, Cancer cell.

[14]  S. Pfister,et al.  MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma , 2011, Acta Neuropathologica.

[15]  Toshihiro Kumabe,et al.  Cytogenetic prognostication within medulloblastoma subgroups. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Roland Eils,et al.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.

[17]  D. Bishop,et al.  A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. , 2001, Human molecular genetics.

[18]  S. Kato,et al.  Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection , 2006, Clinical Cancer Research.

[19]  Roger E. Taylor,et al.  Nodule Formation and Desmoplasia in Medulloblastomas—Defining the Nodular/Desmoplastic Variant and Its Biological Behavior , 2007, Brain pathology.

[20]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[21]  Volker Hovestadt,et al.  Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.

[22]  Emmanuel Barillot,et al.  Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics , 2009, The Journal of pathology.

[23]  S. Clifford,et al.  The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials , 2009, British journal of neurosurgery.

[24]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[25]  J. Adolfsson,et al.  Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  J. Mesirov,et al.  Metagene projection for cross-platform, cross-species characterization of global transcriptional states , 2007, Proceedings of the National Academy of Sciences.

[27]  E. Housepian,et al.  An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. , 1969, Radiology.

[28]  J. Crolla,et al.  Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation , 2000, Molecular pathology : MP.

[29]  M. Fischer,et al.  Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. , 2013, Cancer cell.

[30]  Jeremy Stinson,et al.  Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. , 2009, The New England journal of medicine.

[31]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Ellison,et al.  Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients , 2004, Clinical Cancer Research.

[33]  Roger E. Taylor,et al.  Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Vandenberg,et al.  Pleiotropic role for MYCN in medulloblastoma. , 2010, Genes & development.

[35]  A. Berns,et al.  Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2. , 2006, Cancer research.

[36]  Xiao-Jun Ma,et al.  Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma. , 2013, The Journal of molecular diagnostics : JMD.

[37]  D. Ellison,et al.  Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children's Cancer and Leukaemia Group study. , 2011, European journal of cancer.

[38]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[39]  Paul A. Northcott,et al.  DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies , 2013, Acta Neuropathologica.

[40]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[41]  A. Kohlmann,et al.  A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.

[42]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[43]  A. Rust,et al.  Identification of a neuronal transcription factor network involved in medulloblastoma development , 2013, Acta neuropathologica communications.

[44]  T. Roderick,et al.  FVB/N: an inbred mouse strain preferable for transgenic analyses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[45]  F. Speleman,et al.  Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. , 2014, Cancer letters.

[46]  Axel Benner,et al.  Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[48]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[49]  S. Keir,et al.  Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.

[50]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[51]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[52]  David T. W. Jones,et al.  Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.

[53]  M. Roussel,et al.  A mouse model of the most aggressive subgroup of human medulloblastoma. , 2012, Cancer cell.

[54]  F. Netter,et al.  Supplemental References , 2002, We Came Naked and Barefoot.

[55]  T. Björk-Eriksson,et al.  Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  P. Febbo,et al.  An animal model of MYC-driven medulloblastoma. , 2012, Cancer cell.

[57]  M. Shago,et al.  Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  R. Gilbertson,et al.  The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. , 2004, Brain research. Molecular brain research.

[59]  P. Chène.  Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[60]  S. Robinson,et al.  Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. , 2016, Cancer cell.